{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control%2FPlacebo+group&page=22",
    "query": {
      "intervention": "Control/Placebo group",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 5229,
    "total_pages": 523,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control%2FPlacebo+group&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control%2FPlacebo+group&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-10T07:27:32.071Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06049849",
      "title": "Can Patients With Chronic Stroke Regain Living Independence by Daily Energizing With Biophoton Generators",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Stroke"
      ],
      "interventions": [
        {
          "name": "Biophoton Energizing Brain and Whole Body",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "First Institute of All Medicines",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 46,
      "start_date": "2023-10-31",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-08",
      "last_synced_at": "2026-11-10T07:27:32.071Z",
      "location_count": 1,
      "location_summary": "Butler, Pennsylvania",
      "locations": [
        {
          "city": "Butler",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06049849"
    },
    {
      "nct_id": "NCT00141349",
      "title": "Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Impotence"
      ],
      "interventions": [
        {
          "name": "UK-369,003",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 300,
      "start_date": "2005-02",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2006-07-25",
      "last_synced_at": "2026-11-10T07:27:32.071Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tempe, Arizona + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141349"
    },
    {
      "nct_id": "NCT01660243",
      "title": "Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uremic Pruritus"
      ],
      "interventions": [
        {
          "name": "Nalfurafine hydrochloride(MT-9938) 2.5μg",
          "type": "DRUG"
        },
        {
          "name": "Nalfurafine hydrochloride(MT-9938) 5μg",
          "type": "DRUG"
        },
        {
          "name": "Nalfurafine hydrochloride(MT-9938) 10μg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Toray Industries, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2012-09",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2022-02-09",
      "last_synced_at": "2026-11-10T07:27:32.071Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • New York, New York • Rosedale, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rosedale",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01660243"
    },
    {
      "nct_id": "NCT01387087",
      "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects",
        "Pharmacokinetics of ASP015K"
      ],
      "interventions": [
        {
          "name": "ASP015K",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2008-07",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2011-07-04",
      "last_synced_at": "2026-11-10T07:27:32.071Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01387087"
    },
    {
      "nct_id": "NCT05014438",
      "title": "A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "BMS-986166",
          "type": "DRUG"
        },
        {
          "name": "Branebrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-08-17",
      "completion_date": "2022-08-22",
      "has_results": true,
      "last_update_posted_date": "2023-10-18",
      "last_synced_at": "2026-11-10T07:27:32.071Z",
      "location_count": 17,
      "location_summary": "Fremont, California • Brandon, Florida • Coral Gables, Florida + 14 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Margate",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05014438"
    },
    {
      "nct_id": "NCT01730768",
      "title": "A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "AQW051",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 147,
      "start_date": "2012-09",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2020-12-24",
      "last_synced_at": "2026-11-10T07:27:32.071Z",
      "location_count": 13,
      "location_summary": "Garden Grove, California • Glendale, California • National City, California + 9 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Pico Rivera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01730768"
    },
    {
      "nct_id": "NCT04909021",
      "title": "Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus (RSV)"
      ],
      "interventions": [
        {
          "name": "Investigational RSV vaccine MV-012-968 (Dosage 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational RSV vaccine MV-012-968 (Dosage 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (single-dose)",
          "type": "OTHER"
        },
        {
          "name": "Placebo (two-dose)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Meissa Vaccines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "36 Months",
        "sex": "ALL",
        "summary": "6 Months to 36 Months"
      },
      "enrollment_count": 63,
      "start_date": "2021-06-03",
      "completion_date": "2023-10",
      "has_results": false,
      "last_update_posted_date": "2022-08-02",
      "last_synced_at": "2026-11-10T07:27:32.071Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04909021"
    },
    {
      "nct_id": "NCT01520909",
      "title": "Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 92,
      "start_date": "2012-03",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2015-03-10",
      "last_synced_at": "2026-11-10T07:27:32.071Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • St. Petersburg, Florida • Brooklyn, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01520909"
    },
    {
      "nct_id": "NCT02804763",
      "title": "A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus (SLE)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dapirolizumab pegol (DZP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma S.P.R.L.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2016-06-02",
      "completion_date": "2018-11-19",
      "has_results": true,
      "last_update_posted_date": "2021-06-30",
      "last_synced_at": "2026-11-10T07:27:32.071Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • El Cajon, California • Huntington Beach, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02804763"
    },
    {
      "nct_id": "NCT07054515",
      "title": "A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Niemann-Pick Type C Disease",
        "GM1 Gangliosidosis",
        "GM2 Gangliosidosis"
      ],
      "interventions": [
        {
          "name": "AZ-3102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Azafaros B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2025-06-30",
      "completion_date": "2028-06-14",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-10T07:27:32.071Z",
      "location_count": 5,
      "location_summary": "Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07054515"
    }
  ]
}